Experiences with the oral antidiabetic agent, Glurenorm, in diabetics with kidney diseases
Uglesic, A.; Ljahnicky, N.
Medizinische Monatsschrift 29(9): 408-411
1975
ISSN/ISBN: 0025-8474 PMID: 1102900 Document Number: 87974
Document emailed within 1 workday
Related Documents
Grujić, M.; Rizvanbegović, B.; Perinović, M.; Perinović, I.D. 1976: Glurenorm a new peroral antidiabetic agent belonging to the group of sulfonylurea compounds Medicinski Arhiv 30(2): 119-121Sieberová, R. 1971: Clinical experiences with administration of oral antidiabetic agent Buformin Casopis Lekaru Ceskych 110(18): 420-421
Behpour, A. 1980: Diabetes in adults and old age. Treatment with an oral antidiabetic agent Zfa. Zeitschrift für Allgemeinmedizin 56(22): 1412-1414
D'Onofrio, F.; Pempinello, R.; Romis, L. 1972: Clinical and metabolic observations with a new synthetic oral antidiabetic agent, glipizide Arzneimittel-Forschung 22(11): 1879-1881
Leubner, H. 1973: Results of a clinical test on the oral antidiabetic agent glibornuride (Ro 6-4563) Wiener Medizinische Wochenschrift 123(17): 277-282
Schmitt, E.W.; Nijssen, J. 1978: Glibornuride--field study on an oral antidiabetic agent. Results of therapy with gluboride in a large number of patients Die Medizinische Welt 29(29-30): 1170-1174
Voss, D.; Fuchs, G.; Schneider, D.; Schneider, J. 1972: Effect of the oral antidiabetic agent glibornuride on blood coagulation, blood platelets, and fibrinolysis Arzneimittel-Forschung 22(Suppl 12a): 2219
Fabbian, F.; De Giorgi, A.; Monesi, M.; Tiseo, R.; Storari, A.; Mallozzi Menegatti, A.; Pala, M.; Tomasi, F.; Portaluppi, F.; Manfredini, R. 2014: Prescription of oral antidiabetic drugs in K/DIGO chronic kidney disease stage 3 and 4: a single centre report Minerva Urologica e Nefrologica 66(1): 69-75
Neviani, V.; Tosi, P.; Prampolini, M.L. 1976: 1st experiences with the clinical use of a new beta-blocking agent (tolamolol) in some heart diseases La Clinica Terapeutica 77(5): 451-458
Mlochowski, J.; Belec, C. 1972: The importance of Krynica mineral waters in the treatment of oral diseases in diabetics Czasopismo Stomatologiczne 25(4): 407-412
Maeshiba, Y.; Kiyota, Y.; Yamashita, K.; Yoshimura, Y.; Motohashi, M.; Tanayama, S. 1997: Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys Arzneimittel-Forschung 47(1): 29-35
Redlich, H.; Ganter, H. 1977: 1st experiences with computerized tomography in the diagnosis of kidney diseases Helvetica Chirurgica Acta 44(3): 241-246
Jervell, J. 1976: Oral anti-diabetics--dangerous drugs for diabetics? Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 96(22): 1149
Vendl, L.; Novotná, M. 1974: Experiences with the balneotherapy of kidney and urinary tract diseases in children in Czechoslovakia Kinderarztliche Praxis 42(1): 36-41
Gaber, A.O.; el-Gebely, S.; Sugathan, P.; Elmer, D.S.; Hathaway, D.K.; McCully, R.B.; Shokouh-Amiri, M.H.; Burlew, B.S. 1995: Changes in cardiac function of type I diabetics following pancreas-kidney and kidney-alone transplantation Transplantation Proceedings 27(1): 1322-1323
Johansen, K. 2001: New oral antidiabetic glitazones Ugeskrift for Laeger 164(1): 76-77
Hepp, K.D. 1983: Fenfluramine as an oral antidiabetic Münchener Medizinische Wochenschrift 125(46): 126-127
Schroner, Z.; Javorsky, M.; Kozarova, M.; Tkac, I. 2011: Pharmacogenetics of oral antidiabetic treatment Bratislavske Lekarske Listy 112(8): 441-446
Schumm-Draeger, P-Maria. 2006: Current treatment with oral antidiabetic agents MMW Fortschritte der Medizin 148(9): 33-35
Haslbeck, M. 1979: New aspects of therapy with oral antidiabetic agents Wiener Medizinische Wochenschrift 199(24): 689-695